Abstract
Phase I trials historically involve heavily pretreated patients (pts) with no more effective therapeutic options available and generally with poor expected outcomes (objective response rate (ORR): 9% and mOS: 9.9 mo, Arkenau et. al, BJH 2008). Phase I trials evolved over the past years and are now widely considered. However, there is scare data regarding phase I cancer centers activity and outcomes of pts enrolled into modern phase I trials. Here, we sought to provide an overview of pts inclusions and outcomes into early phase trials at Gustave Roussy (GR) over the last 5 years.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
